Industry news

Hepatitis B therapeutics market to rise to $3b by 2024, says GlobalData

Victoria White / Europian Pharmaceutical Review

According to the company’s latest report, Hepatitis B Virus (HBV) Therapeutics – Global Drug Forecast and Market Analysis to 2024, this expansion, which will occur over the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan, and China, will be slight due to the patent expiration of all existing branded drugs in the chronic hepatitis B therapeutics space during the forecast period, and continued low diagnosis and treatment rates of the disease.

28 January 2016

Avera Medical Group and Epic Sciences collaborate on cancer precision medicine clinical trials

Epic Sciences, Inc. and Avera Medical Group announced today a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast cancer clinical trials.

Key Southeast Asia markets show strong potential punch in 2016

EJ Lane / FeircePharmaAsia

Outside of the main markets in China, Japan and India in Asia are closely followed plays in Indonesia, Thailand, Malaysia and Vietnam with the last two among 12 nations that signed the Trans-Pacific Partnership (TPP) trade pact.

FDA finally speeds up approval for ovarian cancer drugs

Snehal Chougule, Allied Market Research / Europian Pharmaceutical Review

The article, published in The New York Times earlier this year, said that the death of Dr Richard Pazdur’s wife, Mary, who battled ovarian cancer for three years, finally forced the US Food and Drug Administration (FDA) to work faster at testing and approving new drugs.

Pharma calls for collective action to combat antimicrobial resistance

Victoria White / Europian Pharmaceutical Review

The declaration outlines for the first time how industry and governments can work together to support sustained innovation to address the growing problem of AMR by which bacteria and microbes become resistant to regularly used drugs, making common yet life-threatening infections difficult or even impossible to treat. 

Politics and Pricing Will Challenge Manufacturers in 2016

Jill Wechsler / BioPharm International

The escalating attack on rising expenditures for prescription drugs and biologics is prompting more proposals from Congress and political candidates to strengthen oversight of biopharmaceutical development, manufacturing, and marketing. 

Big Pharma consortium rolls out clinical trial investigator platform

Nick Paul Taylor / Fierce Biotech IT

Big Pharma consortium TransCelerate BioPharma has released a portal through which research sites can interact with multiple clinical trial sponsors. The portal is intended to free clinical trial sites from the duplicated workload and administrative burdens associated with using a different portal for each of the sponsors with which they work.

2015: A banner year for personalized medicine

Emma Van Hook / PhRMA

2015 was a record year for personalized medicine approvals, according to a new analysis  from the Personalized Medicine Coalition (PMC). This news confirms the growing role of personalized medicine as an approach to treatment that can improve outcomes for patients and also create important efficiencies in the health care system. Personalized medicine is an emerging field of medicine that uses diagnostic tools to identify specific biological markers to help assess which medical treatments and procedures will be best for each patient.

$58.8 Billion in Venture Capital Invested Across U.S. in 2015, According to the MoneyTree Report

PWC

The venture capital ecosystem deployed $58.8 billion across the United States in 2015, marking the second highest full year total in the last 20 years, according to the MoneyTree™ Report from PricewaterhouseCoopers LLP (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. For the fourth quarter of 2015, venture capitalists invested $11.3 billion into 962 deals, down 32 percent in dollars and 16 percent in deals compared with the third quarter when $16.6 billion was invested in 1,149 deals. The fourth quarter also marks the eighth consecutive quarter of more than $10 billion of venture capital invested in a single quarter, but also represents the smallest amount invested since the third quarter of 2014.

Top Boston Sci exec says more women are needed in device clinical trials

Varun Saxena / FierceMedicalDevices

Dr. Ken Stein, the chief medical officer of Boston Scientific's ($BSX) rhythm management division, said that industry and the healthcare system are not doing a good job of ensuring women are adequately treated with cardiology devices like pacemakers and implantable defibrillators.